Relapsed Or Refractory Acute Myeloid Leukemia Aml With A Susceptible Nucleophosmin 1 Npm1 Mutation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapsed or refractory acute myeloid leukemia aml with a susceptible nucleophosmin 1 npm1 mutation. 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2036. Daily refresh.

1
Approved drugs
16
Active US patents
41/100
Avg vulnerability
—
Annual revenue covered

Originators in Relapsed Or Refractory Acute Myeloid Leukemia Aml With A Susceptible Nucleophosmin 1 Npm1 Mutation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Kura 16 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapsed or refractory acute myeloid leukemia aml with a susceptible nucleophosmin 1 npm1 mutation. Each bar = one year. Y-axis scaled to peak year (3 patents).

2
36
3
37
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Komzifti
ZIFTOMENIB
 Kura 16 41 — 2036-03-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10174041 Komzifti method of use 58 2036-03-16
10869868 Komzifti method of use 58 2037-01-26
11673898 Komzifti method of use 58 2037-03-15
11944627 Komzifti method of use 58 2038-09-06
12410184 Komzifti method of use 58 2044-07-16
12521396 Komzifti formulation 38 2044-07-16
10077271 Komzifti composition of matter 0 2036-03-16
10781218 Komzifti composition of matter 0 2037-03-15

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10781218 Komzifti composition of matter 0 2037-03-15
10077271 Komzifti composition of matter 0 2036-03-16
12521396 Komzifti formulation 38 2044-07-16
12410184 Komzifti method of use 58 2044-07-16
11944627 Komzifti method of use 58 2038-09-06
11673898 Komzifti method of use 58 2037-03-15
10869868 Komzifti method of use 58 2037-01-26
10174041 Komzifti method of use 58 2036-03-16

Related